Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

8.29
-0.7000-7.79%
Post-market: 8.28-0.0100-0.12%19:57 EDT
Volume:27.81M
Turnover:238.14M
Market Cap:3.76B
PE:-11.75
High:9.30
Open:9.08
Low:8.15
Close:8.99
52wk High:9.36
52wk Low:1.76
Shares:452.97M
Float Shares:394.00M
Volume Ratio:1.25
T/O Rate:7.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7058
EPS(LYR):-1.0941
ROE:-40.36%
ROA:-20.31%
PB:5.10
PE(LYR):-7.58

Loading ...

Iovance Grants 240,135 Inducement Stock Options Priced at $8.99 Per Share

Reuters
·
Yesterday

Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Yesterday

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Yesterday

Movement Alert|Iovance Biotherapeutics, Inc. Falls 8.06% in Regular Trading, UBS Report Flags Competitive Headwinds for Amtagvi

Market Focus
·
Yesterday

Iovance's Growth Outlook Clouded as Amtagvi Faces Competition Hurdles, UBS Says

MT Newswires Live
·
Aug 21

Iovance Biotherapeutics Price Target Raised to $7.00/Share from $4.00 by UBS

Dow Jones
·
Aug 20

Movement Alert|Iovance Biotherapeutics, Inc. Rises 9.07% in Regular Trading, Q2 Earnings Beat and UBS Price Target Raise Fuel Momentum

Market Focus
·
Aug 20

UBS Adjusts Iovance Biotherapeutics Price Target to $7 From $4, Maintains Neutral Rating

MT Newswires Live
·
Aug 20

Iovance Biotherapeutics price target raised to $7 from $4 at UBS

TIPRANKS
·
Aug 20

Iovance Biotherapeutics (IOVA) Stock Could Be Rich Following Its 217% Run

Simply Wall St.
·
Aug 20

Movement Alert|Iovance Biotherapeutics, Inc. Rises 10.03% in Regular Trading, Q2 Earnings Beat Fuels Continued Upward Momentum

Market Focus
·
Aug 20

Iovance Biotherapeutics (IOVA) Earnings Put Its Valuation Back In Focus

Simply Wall St.
·
Aug 19

Iovance Biotherapeutics put volume heavy and directionally bearish

TIPRANKS
·
Aug 17

Iovance Biotherapeutics (IOVA) Stock Price Trails Record Revenue And Margin Gains

Simply Wall St.
·
Aug 08

Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock is Tumbling.

Dow Jones
·
Aug 08

Iovance Biotherapeutics is Maintained at Market Outperform by Citizens

Dow Jones
·
Aug 07

Iovance Biotherapeutics price target raised to $8 from $5 at Citizens

TIPRANKS
·
Aug 07

Iovance Biotherapeutics price target raised to $13 from $11 at Barclays

TIPRANKS
·
Aug 07

Barclays Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)

TIPRANKS
·
Aug 07

US FDA Approves Replimune's Skin Cancer Drug

Reuters
·
Aug 07